The panelist discusses Vowst, an FDA-approved live microbiota therapeutic that works by introducing healthy donor-derived gut ...

Clostridioides difficile is a type of bacteria that often affects people who have been taking antibiotics, GST Micro LLC ...

The panelist discusses Rebyota, a treatment approved by the FDA for preventing recurrent Clostridioides difficile infections in adults who have completed antibiotic treatment for recurrent C difficile ...

The following is a summary of “Oral Capsule FMT Combined With Bezlotoxumab Is a Successful Rescue Protocol Following Failure ...

Pharmaceuticals announced updates on Phase 3 Readiness for Ibezapolstat in C. difficile Infection based on recent FDA and EMA ...

Recurrent C. diff infection is when you contract a C. diff infection 2 to 8 weeks after completing treatment for a previous one. C. diff relapse is a recurrence of the same strain, while ...

Dan Ilges [Opens in a new window], ...

OpenBiome, which provides fecal microbiota transplantation material for US patients with severe/fulminant C difficile ...

Clostridium difficile infection (CDI ... Although metronidazole and vancomycin are and have been the mainstay treatment options for CDI, there are some unmet medical and therapeutical needs.

Following the previously announced successful End of Phase 2 Meeting achieving agreement with FDA on non-clinical and clinical Phase 3-readiness, Acurx has now also received written positive feedback ...